The Evaluation of Lncrna Gas5 Expression in Type2 Diabetic Patients

Background and aim: diabetes mellitus comprises of a series of metabolic disorders featured by abnormally high glucose level in blood. type 2 diabetes mellitus (t2dm) develops because of insulin resistance of human organs and insufficient secretion of insulin from pancreaticβ-cells. the lncrna growth-arrest specific transcript 5 (gas5) is a 5′-terminal oligopyrimidine class of genes which regulates cell growth, proliferation and survival. gas5 acts as a riborepressor by repressing transcription of glucocorticoid receptor. it has been shown that inhibition of mtor can increase the level of gas5. in addition, it interferes with carbohydrate metabolism and increases likelihood of developing diabetes. however, the exact role of gas5 in diabetes is not fully understood. the aim of this study was to investigate the expression level of gas5 in patients with t2dm. methods: a total of 40 genetically unrelated subjects including 20 healthy controls and 20 patients with t2dm participated in this study. total rna was isolated from blood samples, using trizol according to the manufacturer's protocol. synthesis of cdna was performed. primers for real time pcr were designed, synthesized and specificity of the binding of primers was confirmed by gel electrophoresis. in this study the gapdh gene was used as an internal control gene. the lncrna gas5 expression level was evaluated by real-time pcr and the results were analyzed by spss, prism. results: we observe a marked decrease in gas5 expression in diabetic samples compared to non-diabetic (p<0.05). conclusion: in conclusion, this is a first report of gas5 expression in t2dm. more research is needed to fully elucidate the underlying molecular mechanisms of t2dm susceptibility.